 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | LX1001 / Weill Cornell Medical College, Lexeo Therap
Trial completion date, Trial primary completion date, Gene therapy: LEADLTFU: Long-Term Follow-up of Gene Therapy for APOE4 Homozygote Alzheimer's Disease (clinicaltrials.gov) - Dec 31, 2023
P1, N=15, Recruiting, Sponsor: Lexeo Therapeutics
- | LX1001 / Weill Cornell Medical College, Lexeo Therap
Trial completion date, Trial primary completion date, Gene therapy: Gene Therapy for APOE4 Homozygote of Alzheimer's Disease (clinicaltrials.gov) - Dec 31, 2023
P1/2, N=15, Active, not recruiting, Sponsor: Lexeo Therapeutics
- | LX1001 / Weill Cornell Medical College, Lexeo Therap
Enrollment closed, Gene therapy: Gene Therapy for APOE4 Homozygote of Alzheimer's Disease (clinicaltrials.gov) - Nov 14, 2023
P1/2, N=15, Active, not recruiting, Sponsor: Lexeo Therapeutics
Recruiting --> Active, not recruiting
- || LX1001 / Weill Cornell Medical College, Lexeo Therap
Enrollment open, Gene therapy: LEADLTFU: Long-Term Follow-up of Gene Therapy for APOE4 Homozygote Alzheimer's Disease (clinicaltrials.gov) - Jul 3, 2023
P1, N=15, Recruiting, Sponsor: Lexeo Therapeutics
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- | LX1001 / Weill Cornell Medical College, Lexeo Therap
Trial completion date, Trial primary completion date, Gene therapy: Gene Therapy for APOE4 Homozygote of Alzheimer's Disease (clinicaltrials.gov) - May 12, 2023
P1/2, N=15, Recruiting, Sponsor: Lexeo Therapeutics
Not yet recruiting --> Recruiting Trial completion date: Jun 2024 --> Dec 2024 | Trial primary completion date: Jun 2023 --> Dec 2023
- | LX1001 / Weill Cornell Medical College, Lexeo Therap
Phase classification, Trial completion date, Trial primary completion date, Gene therapy: Gene Therapy for APOE4 Homozygote of Alzheimer's Disease (clinicaltrials.gov) - Dec 2, 2022
P1/2, N=15, Recruiting, Sponsor: Lexeo Therapeutics
Trial completion date: Jun 2024 --> Dec 2024 | Trial primary completion date: Jun 2023 --> Dec 2023 Phase classification: P1 --> P1/2 | Trial completion date: Sep 2024 --> Apr 2024 | Trial primary completion date: Sep 2023 --> Apr 2023
- LX1001 / Weill Cornell Medical College, Lexeo Therap
A Phase 1, Open-Label, 52-Week, Multicenter Study to Evaluate the Safety and Biochemical Efficacy of AAV Gene Therapy (LX1001) in Patients with APOE4 Homozygote Alzheimer’s Disease – Interim Data (Grand Ballroom AB - Tower 2) - Oct 5, 2022 - Abstract #CTAD2022CTAD_302;
Initial data in the low-dose cohort supports technical feasibility of conferring APOE2 expression in the CNS of human APOE4 homozygotes and indicates that there were no serious adverse events from either CSF delivery of LX1001 or from documented expression of APOE2 in these subjects. These data support further exploration of APOE2 gene therapy as a potential therapeutic for APOE4 homozygous AD patients.
- || LX1001 / Weill Cornell Medical College, Lexeo Therap
Trial initiation date, Gene therapy: LEADLTFU: Long-Term Follow-up of Gene Therapy for APOE4 Homozygote Alzheimer's Disease (clinicaltrials.gov) - Aug 16, 2022
P1, N=15, Not yet recruiting, Sponsor: Lexeo Therapeutics
These data support further exploration of APOE2 gene therapy as a potential therapeutic for APOE4 homozygous AD patients. Initiation date: Jun 2022 --> Sep 2022
- || LX1001 / Weill Cornell Medical College, Lexeo Therap
New P1 trial, Gene therapy: LEADLTFU: Long-Term Follow-up of Gene Therapy for APOE4 Homozygote Alzheimer's Disease (clinicaltrials.gov) - May 31, 2022
P1, N=15, Not yet recruiting, Sponsor: Lexeo Therapeutics
- | LX1001 / Weill Cornell Medical College, Lexeo Therap
Trial completion date, Trial primary completion date, Gene therapy: Gene Therapy for APOE4 Homozygote of Alzheimer's Disease (clinicaltrials.gov) - Apr 5, 2022
P1, N=15, Recruiting, Sponsor: Lexeo Therapeutics
Initiation date: Jun 2022 --> Sep 2022 Trial completion date: Jan 2024 --> Sep 2024 | Trial primary completion date: Jan 2023 --> Sep 2023
- | LX1001 / Weill Cornell Medical College, Lexeo Therap
Trial completion date, Gene therapy: Gene Therapy for APOE4 Homozygote of Alzheimer's Disease (clinicaltrials.gov) - Jan 21, 2022
P1, N=15, Recruiting, Sponsor: Lexeo Therapeutics
Trial completion date: Jan 2024 --> Sep 2024 | Trial primary completion date: Jan 2023 --> Sep 2023 Trial completion date: Jan 2023 --> Jan 2024
- | LX1001 / Weill Cornell Medical College, Lexeo Therap
Trial completion date, Trial primary completion date, Gene therapy: Gene Therapy for APOE4 Homozygote of Alzheimer's Disease (clinicaltrials.gov) - Feb 2, 2021
P1, N=15, Recruiting, Sponsor: Weill Medical College of Cornell University
Trial completion date: Jan 2023 --> Jan 2024 Trial completion date: Dec 2021 --> Jan 2023 | Trial primary completion date: Dec 2020 --> Jan 2023
- | LX1001 / Weill Cornell Medical College, Lexeo Therap
Enrollment open, Gene therapy: Gene Therapy for APOE4 Homozygote of Alzheimer's Disease (clinicaltrials.gov) - Aug 28, 2019
P1, N=15, Recruiting, Sponsor: Weill Medical College of Cornell University
Trial completion date: Dec 2021 --> Jan 2023 | Trial primary completion date: Dec 2020 --> Jan 2023 Not yet recruiting --> Recruiting
- | LX1001 / Weill Cornell Medical College, Lexeo Therap
Trial initiation date, Gene therapy: Gene Therapy for APOE4 Homozygote of Alzheimer's Disease (clinicaltrials.gov) - Jul 28, 2019
P1, N=15, Not yet recruiting, Sponsor: Weill Medical College of Cornell University
Not yet recruiting --> Recruiting Initiation date: Jun 2019 --> Sep 2019
- | LX1001 / Weill Cornell Medical College, Lexeo Therap
Trial initiation date, Gene therapy: Gene Therapy for APOE4 Homozygote of Alzheimer's Disease (clinicaltrials.gov) - Jan 17, 2019
P1, N=15, Not yet recruiting, Sponsor: Weill Medical College of Cornell University
Initiation date: Jun 2019 --> Sep 2019 Initiation date: Dec 2018 --> Jun 2019
- | LX1001 / Weill Cornell Medical College, Lexeo Therap
Trial initiation date, Gene therapy: Gene Therapy for APOE4 Homozygote of Alzheimer's Disease (clinicaltrials.gov) - Oct 11, 2018
P1, N=15, Not yet recruiting, Sponsor: Weill Medical College of Cornell University
Initiation date: Dec 2018 --> Jun 2019 Initiation date: Sep 2018 --> Dec 2018
- | LX1001 / Weill Cornell Medical College, Lexeo Therap
New P1 trial, Gene therapy: Gene Therapy for APOE4 Homozygote of Alzheimer's Disease (clinicaltrials.gov) - Aug 15, 2018
P1, N=15, Not yet recruiting, Sponsor: Weill Medical College of Cornell University